HVTN 138/HPTN 098

A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of the monoclonal antibody CAP256V2LS administered alone and in combination with VRC07-523LS via intravenous or subcutaneous infusions in healthy, HIV-1 uninfected adult participants